4d Molecular Therapeutics, INC Form 4 insider transactions

David Kirn, See Remarks and a Director of 4D Molecular Therapeutics, Inc., sold 12,415 shares of common stock on August 3, 2026 for $10.05 per share.

David Kirn, See Remarks and a Director of 4D Molecular Therapeutics, Inc., sold 58,333 shares of common stock on July 9, 2026.

Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, reports transactions involving the purchase and sale of company stock.

Shawn Tomasello, a Director at 4D Molecular Therapeutics, Inc., acquired 50,000 stock options under the company's non-employee director compensation program.

Charles Theuer, a Director at 4D Molecular Therapeutics, Inc., has been granted 50,000 stock options as part of the company's non-employee director compensation program.

Nancy Miller-Rich, a Director at 4D Molecular Therapeutics, Inc., was granted 50,000 stock options as part of the company's non-employee director compensation program.

Susannah Gray, a Director at 4D Molecular Therapeutics, received a stock option grant for 50,000 shares.

John F. Milligan, a Director at 4D Molecular Therapeutics, Inc., has been granted 75,000 stock options as part of the company's non-employee director compensation program.

Glenn Sblendorio, a Director at 4D Molecular Therapeutics, Inc., was granted 50,000 stock options with an exercise price of $9.42.

Jacob Chacko, a Director at 4D Molecular Therapeutics, Inc., was granted stock options for 50,000 shares.

David Kirn, Director and Officer of 4D Molecular Therapeutics, Inc., reported a transaction involving the sale of 1,922 shares of common stock on June 1, 2026, executed under a pre-arranged 10b5-1 trading plan.

4D Molecular Therapeutics' CEO, David Kirn, was granted 750,000 stock options with a $9.88 exercise price, vesting over four years.

Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, received an option to purchase 217,000 shares of common stock at an exercise price of $9.88.

Christopher Paul Simms, Chief Commercial and Business Officer of 4D Molecular Therapeutics, received a grant of 219,000 stock options.

Ashoo Gupta, VP of Finance and Controller at 4D Molecular Therapeutics, reported the conversion of Restricted Stock Units into common stock and subsequent sales to cover tax obligations.

4D Molecular Therapeutics director Glenn Sblendorio received a grant of 45,000 stock options with a $7.3 exercise price, vesting over three years.

Ashoo Gupta, VP of Finance and Controller at 4D Molecular Therapeutics, reported the conversion of Restricted Stock Units into common stock and subsequent sales to cover tax obligations.

4D Molecular Therapeutics' Chief Legal Officer, Scott Bizily, executed a pre-planned sale of 1,635 common shares following the exercise of stock options.

4D Molecular Therapeutics Director Charles Theuer exercised options to acquire 9,333 shares of common stock at $1.14 per share.

Kristian Humer, Chief Financial Officer of 4D Molecular Therapeutics, Inc., was granted 480,000 stock options with an exercise price of $10.51, vesting over four years.

4D Molecular Therapeutics' Chief Legal Officer, Scott Bizily, exercised stock options and subsequently sold an equal number of shares under a pre-arranged 10b5-1 trading plan.

Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, exercised stock options and subsequently sold a portion of his common stock holdings.

4D Molecular Therapeutics' Chief Legal Officer, Scott Bizily, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged trading plan.

Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, Inc., sold 2,408 shares of common stock at $10 per share under a pre-arranged 10b5-1 trading plan.

4D Molecular Therapeutics' Chief Legal Officer, Scott Bizily, sold 2,407 shares of common stock at $8 per share under a pre-arranged 10b5-1 trading plan.

Jacob Chacko, a Director at 4D Molecular Therapeutics, Inc. (FDMT), was granted 22,500 stock options with an exercise price of $4.15 as part of the company's non-employee director compensation program.

Susannah Gray, a Director at 4D Molecular Therapeutics, Inc., was granted 22,500 stock options with an exercise price of $4.15 as part of the company's non-employee director compensation program.

Shawn Tomasello, a Director at 4D Molecular Therapeutics, Inc., was granted 22,500 stock options with an exercise price of $4.15 as part of the company's non-employee director compensation program.

Director Charles Theuer of 4D Molecular Therapeutics, Inc. was granted 22,500 stock options at an exercise price of $4.15 as part of the company's non-employee director compensation program.

Nancy Miller-Rich, a Director at 4D Molecular Therapeutics, Inc., was granted 22,500 stock options with an exercise price of $4.15 as part of the company's non-employee director compensation program.